Esketamine Nasal Spray HCPCS G2083 Billing

Key Takeaways

HCPCS Code G2083 covers an outpatient esketamine (Spravato) session for established patients requiring greater than 56 mg nasal self-administration, bundled with 2-hour post-administration observation.

G2083 is billed per session; the provider must both supervise the self-administration AND supply the drug to report this code.

G2083 differs from G2082 by dose threshold: G2082 covers up to 56 mg, G2083 covers greater than 56 mg per session.

Effective January 1, 2026, J0013 replaced S0013 as the permanent HCPCS drug code for esketamine for Medicaid and commercial payers outside Medicare.

Pabau’s claims management software helps psychiatry and mental health practices track bundled service codes, REMS documentation, and per-session billing for Spravato workflows.

Most Spravato billing errors happen before the claim is even submitted. Providers misapply the dose threshold, miss the ICD-10 pairing requirement, or report an E/M code instead of the bundled G-code – and the denial arrives weeks later. Psychiatry practice management demands precise coding, and HCPCS Code G2083 is one of the more nuanced codes in that workflow. This guide covers the full descriptor, the G2082 vs G2083 distinction, Medicare reimbursement figures, ICD-10 pairing, REMS requirements, and the J0013 transition that took effect in 2026.

HCPCS Code G2083: Official descriptor and clinical context

HCPCS Code G2083 is a Level II G-code established and maintained by the Centers for Medicare and Medicaid Services (CMS). The full descriptor reads: “Office or other outpatient visit for the evaluation and management of an established patient that requires the supervision of a physician or other qualified health care professional and provision of greater than 56 mg esketamine nasal self-administration, includes 2 hours post-administration observation.”

Several elements of that descriptor carry hard billing consequences:

• Established patient only. G2083 cannot be reported for new patients. Initial evaluations are billed separately before Spravato treatment begins.
• Dose threshold: greater than 56 mg. A session at exactly 56 mg falls under G2082. G2083 applies when the administered dose exceeds that threshold (typically 84 mg).
• Bundled service. The code wraps together the E/M component, drug supervision, and the mandatory 2-hour post-administration observation. Do not separately bill an E/M code for the same session.
• Provider must supply the drug. Per Janssen’s official coding overview brochure for SPRAVATO, when the supervising healthcare professional does not also provide the drug, the provider cannot report G2082 or G2083. Split-billing scenarios (pharmacy-supplied) require a different approach.

Spravato (esketamine) carries FDA approval for treatment-resistant depression (TRD) in adults and for major depressive disorder with acute suicidal ideation or behavior (MDSI). Both indications are relevant to code selection and ICD-10 pairing. Strong mental health EMR workflows keep these indication records accessible at billing time.

G2082 vs G2083: Choosing the correct dose-based code

These two codes are structurally identical except for the dose threshold. Understanding the split is fundamental to avoiding under-coding or over-coding either session type.

In clinical practice, the 56 mg dose applies to titration sessions and some induction sessions. The 84 mg dose (greater than 56 mg) is the standard maintenance dose for most patients, making G2083 the more commonly reported of the two codes once treatment is underway. CMS set the relative values for both codes using a building block methodology that sums the values associated with the component services, per CMS Manual System Transmittal R10505CP.

Neither code should be billed alongside a separate E/M code for the same encounter. The G-code already bundles that component. Billing both on the same date of service is a common audit trigger. See related outpatient procedure coding guidance for how bundled codes interact with standard E/M workflows.

Documentation requirements for G2083 billing

Spravato is dispensed and administered under a mandatory FDA Risk Evaluation and Mitigation Strategy (REMS) program. That program does not just govern clinical safety – it directly shapes what your documentation must contain for billing to hold up. A claim for G2083 without REMS-compliant records is vulnerable at audit.

Required documentation elements for each G2083 session:

• REMS certification status. The healthcare setting (not just the prescriber) must be enrolled in the SPRAVATO REMS program. Document your certification number and the patient’s REMS enrollment confirmation.
• Dose administered. Explicitly state the mg amount in the clinical note (e.g., “84 mg esketamine nasal spray administered”). This is the primary evidence supporting G2083 over G2082.
• Supervision record. Document that a physician or other qualified healthcare professional was present and supervising throughout the self-administration and observation window.
• 2-hour observation window. Record the observation start and end times. CMS requires the 2-hour window be completed before the patient is discharged.
• Established patient confirmation. Your record should show prior evaluation history, confirming the patient is not being treated as a new patient under this code.
• ICD-10 diagnosis code. Per CMS Local Coverage Article A59249, the claim must pair G2083 with an approved ICD-10-CM diagnosis code aligned with the FDA-approved indications for esketamine.

Consistent, structured documentation protects against both claim denials and retrospective audits. Digital forms that capture session-specific fields (dose, observation times, supervision attestation) remove the manual documentation gap that causes most G2083 denials. Staying current on HIPAA compliance documentation standards also matters for these records, given the sensitive psychiatric context.

Streamline Spravato billing from session to claim

Pabau helps psychiatry and mental health practices document G2083 sessions accurately, track REMS-required fields, and submit claims without the manual rework. See how it fits your workflow.

Book a demo

ICD-10 diagnosis codes that support HCPCS Code G2083

CMS Article A59249 provides a single unified Group 1 list of 12 ICD-10-CM codes that support medical necessity for both G2082 and G2083. CMS does not split this list by FDA indication (TRD vs. MDSI) — all 12 codes apply to both codes. Submitting G2083 with an ICD-10 code outside this approved list is a common denial reason.

• F32.0 — Major depressive disorder, single episode, mild
• F32.1 — Major depressive disorder, single episode, moderate
• F32.2 — Major depressive disorder, single episode, severe without psychotic features
• F32.4 — Major depressive disorder, single episode, in partial remission
• F32.5* — Major depressive disorder, single episode, in full remission (maintenance phase only)
• F32.89 — Other specified depressive episodes
• F33.0 — Major depressive disorder, recurrent, mild
• F33.1 — Major depressive disorder, recurrent, moderate
• F33.2 — Major depressive disorder, recurrent severe without psychotic features
• F33.41 — Major depressive disorder, recurrent, in partial remission
• F33.42* — Major depressive disorder, recurrent, in full remission (maintenance phase only)
• F33.8 — Other recurrent depressive disorders

* F32.5 and F33.42 (full remission codes) are only appropriate during the maintenance phase of treatment. Note that CMS Article A59249 was retired effective December 18, 2025. Providers should confirm the current approved ICD-10 code list directly with their Medicare Administrative Contractor (MAC) and refer to the FDA label for current coverage guidance. The AAPC Codify HCPCS lookup also provides crosswalk information between G2083 and supporting diagnosis codes. For other anxiety-related diagnostic coding in your mental health practice, see our guide on situational anxiety ICD-10 coding.

Medicare reimbursement and fee schedule for HCPCS Code G2083

G2083 reimburses at a higher rate than G2082 because of the greater dose and the correspondingly higher drug cost component bundled into the session. According to billing data cited for 2026, Medicare reimbursement for G2083 averages approximately $1,356.08 nationally. Commercial payer rates average around $1,240 for the same session, though rates vary by contract. Verify current figures using the CMS Physician Fee Schedule lookup tool, which allows you to search by HCPCS code and geographic locality.

Several factors affect your actual reimbursed amount:

• Geographic locality. Medicare adjusts rates using geographic practice cost indices (GPCIs). Urban markets typically reimburse above the national average; rural areas may fall below it.
• Place of service. G2083 is an outpatient code. Billing from a facility setting (hospital outpatient department) versus a non-facility setting (office) produces different payment calculations under the Medicare fee schedule.
• Payer mix. Commercial insurers negotiate rates independently. Some plans follow Medicare rates; others maintain separate fee schedules. Anthem and Highmark have both published Spravato-specific reimbursement policy bulletins that specify G2083 rates for their networks.

Efficient claims management software surfaces these per-session reimbursement discrepancies before they become write-offs, giving billing teams visibility across payer mix for a high-cost bundled session like G2083.

J0013 and S0013: Drug codes used alongside G2083

G2083 bundles the professional service, supervision, and observation components. The drug itself (the esketamine nasal spray cartridges) is billed separately in certain scenarios – particularly when a pharmacy supplies the drug rather than the provider dispensing it directly.

J0013: The 2026 permanent HCPCS drug code for esketamine

Effective January 1, 2026, J0013 became the permanent HCPCS Level II drug code for esketamine nasal spray, replacing the temporary S0013 code. J0013 is billed in 1 mg increments and applies to Medicaid and commercial non-Medicare payers. An 84 mg session would be reported as 84 units of J0013.

For Medicare, the drug component is already bundled into G2082 and G2083 – J0013 is not separately billed on Medicare claims alongside these G-codes. Practices that previously used S0013 for Medicaid or commercial claims needed to transition to J0013 at the start of 2026. Payers that still accept S0013 after the effective date are handling it on a transitional basis; confirm directly with each payer if you are still seeing S0013 accepted.

Split-billing: Pharmacy-supplied drug scenarios

When a pharmacy supplies the Spravato and bills for the drug separately, the provider cannot report G2082 or G2083 for the same session. The pharmacy bills the drug under J0013 (or S0013 pre-2026); the provider bills only for the supervision and observation using alternative codes. This split arrangement requires careful coordination between the dispensing pharmacy and the administering practice to avoid duplicate billing.

The prescription management workflow in your practice system should flag which sessions involve pharmacy-supplied drug versus provider-supplied drug before billing runs. HIPAA security requirements also apply to the communication of dispensing records between pharmacy and provider in these arrangements.

Payer-specific guidelines for G2083

Coverage policies for G2083 are not uniform across payers. Understanding each payer’s requirements before billing reduces denials and avoids retroactive audits.

Medicare

Medicare coverage follows CMS Article A59249 for ICD-10 pairing and the standard HCPCS descriptor requirements. CMS uses the building block methodology (Transmittal R10505CP) to set G2082 and G2083 values. Prior authorization requirements vary by Medicare Advantage plan – commercial MA plans may impose additional PA requirements beyond original Medicare.

TRICARE

TRICARE follows CMS billing guidelines for Spravato, using HCPCS codes G2082 and G2083 rather than E/M codes, per TRICARE provider guidance. Providers billing TRICARE should confirm enrollment in the REMS program and align documentation with CMS standards. Do not substitute E/M codes for the G-codes on TRICARE claims.

Commercial payers (Highmark, Anthem)

Highmark’s Reimbursement Policy Bulletin RP-083 specifies that professional providers use G2082 or G2083 for Spravato claims, consistent with CMS guidance. Anthem’s coding tips for Spravato similarly align professional claims to these G-codes. Both payers have published provider-facing documentation on split-billing rules when a pharmacy supplies the drug. Review the current policy bulletins for each payer in your network, as prior authorization requirements and step therapy criteria (requiring prior antidepressant trials) vary. Organized compliance management within your practice system helps track payer-specific authorization status across a Spravato patient panel.

Conclusion

G2083 billing errors cluster around three points: the dose threshold (reporting G2082 when the dose exceeded 56 mg), missing REMS documentation, and ICD-10 codes outside the A59249 approved list. Getting these right is straightforward once the documentation workflow enforces them at the point of care rather than at claim submission.

Pabau’s claims management tools help mental health and psychiatry practices structure G2083 session documentation, flag required fields before billing, and track per-session reimbursement across payers. To see how Pabau supports Spravato billing workflows, book a demo.

Continue your research

Need a full psychiatric evaluation workflow? Psychiatric evaluation template provides a structured framework for mental health assessments that precede Spravato treatment initiation.

Managing a mental health practice beyond billing? Mental health EMR software covers the full clinical and administrative workflow for psychiatry and therapy practices.

Looking for ICD-10 guidance on related conditions? Situational anxiety ICD-10 coding walks through diagnosis code selection for anxiety presentations that often co-occur with depression.

Frequently Asked Questions